Education
About Us
Working with TipRanks
Follow Us
Ligand Pharmaceuticals Inc (LGND)
NASDAQ:LGND
LGND Stock Chart & Stats
$197.39
-$2.36(-2.14%)
At close: 4:00 PM EST
$197.39
-$2.36(-2.14%)
Day’s Range― - ―
52-Week Range$93.58 - $212.49
Previous CloseN/A
Volume21.09K
Average Volume (3M)222.15K
Market Cap
$3.88B
Enterprise Value$3.44B
Total Cash (Recent Filing)$664.52M
Total Debt (Recent Filing)$451.00M
Price to Earnings (P/E)95.0
Beta0.95
Next Earnings
Mar 04, 2026EPS Estimate
1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.09
Shares Outstanding19,681,720
10 Day Avg. Volume245,136
30 Day Avg. Volume222,145
Financial Highlights & Ratios
PEG Ratio4.53
Price to Book (P/B)2.36
Price to Sales (P/S)11.73
P/FCF Ratio20.58
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue13.70
Enterprise Value/Gross Profit15.94
Enterprise Value/Ebitda34.44
Forecast
1Y Price Target
$243.50Price Target Upside23.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)7.57
Revenue Forecast (FY)$264.01M
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressQTORIN continues its development programs with positive Phase 2 TOIVA data and Palvella plans to seek Breakthrough Therapy Designation for cutaneous venous malformations.
Partnership And Market ExpansionMerck's acquisition of Verona Pharma and investment in Ohtuvayre have driven royalty revenues to Ligand and could provide R&D catalysts in several new indications for the drug beyond COPD.
Revenue And Earnings GrowthLigand Pharma hosted its annual analyst day, providing positive guidance of revenues of $225-$235 million and adjusted EPS of $7.40-$7.65 for 2025, with forecasts of $245-$285 million in revenues and $8.00-$9.00 in earnings for 2026.
Bears Say
Declining RoyaltiesKyprolis and Qarziba royalties are expected to decline modestly in the coming years.
Potential Conflict Of InterestInvestors should be aware of a potential conflict of interest in the report due to the Firm's business with companies covered.
Ligand Pharma News
LGND FAQ
What was Ligand Pharmaceuticals Inc’s price range in the past 12 months?
Ligand Pharmaceuticals Inc lowest stock price was $93.58 and its highest was $212.49 in the past 12 months.
What is Ligand Pharmaceuticals Inc’s market cap?
Ligand Pharmaceuticals Inc’s market cap is $3.88B.
When is Ligand Pharmaceuticals Inc’s upcoming earnings report date?
Ligand Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2026 which is in 68 days.
How were Ligand Pharmaceuticals Inc’s earnings last quarter?
Ligand Pharmaceuticals Inc released its earnings results on Nov 06, 2025. The company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $1.928 by $1.162.
Is Ligand Pharmaceuticals Inc overvalued?
According to Wall Street analysts Ligand Pharmaceuticals Inc’s price is currently Undervalued.
Does Ligand Pharmaceuticals Inc pay dividends?
Ligand Pharmaceuticals Inc pays a Notavailable dividend of $0.456 which represents an annual dividend yield of N/A. See more information on Ligand Pharmaceuticals Inc dividends here
What is Ligand Pharmaceuticals Inc’s EPS estimate?
Ligand Pharmaceuticals Inc’s EPS estimate is 1.5.
How many shares outstanding does Ligand Pharmaceuticals Inc have?
Ligand Pharmaceuticals Inc has 19,681,720 shares outstanding.
What happened to Ligand Pharmaceuticals Inc’s price movement after its last earnings report?
Ligand Pharmaceuticals Inc reported an EPS of $3.09 in its last earnings report, beating expectations of $1.928. Following the earnings report the stock price went up 9.371%.
Which hedge fund is a major shareholder of Ligand Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in LGND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$243.50 (23.36% Upside)
$243.50 (23.36% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 34.1%
Last 30 Days ▲ 34.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.45%
12-Months-Change
Fundamentals
Return on Equity
5.42%
Trailing 12-Months
Asset Growth
54.66%
Trailing 12-Months
Company Description
Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
LGND Company Deck
LGND Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant growth in core revenue and EPS, an increase in full-year guidance, and successful financial transactions. However, there are some concerns related to increased operating expenses and limited information on the ZELSUVMI launch.View all LGND earnings summariesLGND Stock 12 Month Forecast
Average Price Target
$243.50
▲(23.36% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---